Inactive Instrument

News PledPharma AB (publ) Nasdaq Stockholm

Equities

End-of-day quote Nasdaq Stockholm Other stock markets
- ^SEK	-

20/06	Transcript : Egetis Therapeutics AB - Special Call
19/06	Egetis Therapeutics AB Announces Topline Results of the Phase 2 Triac Trial II with Emcitate for MCT8 Deficiency	CI

Summary

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

European Thyroid Association recommends tiratricol (Emcitate®) as long-term therapy for all patients with MCT8 deficiency in new guidelines	17/07	AQ
Transcript : Egetis Therapeutics AB - Special Call	20/06
Egetis announces topline results of the Phase 2 Triac Trial II with Emcitate® (tiratricol) for MCT8 deficiency	19/06	AQ
Egetis Therapeutics AB Announces Topline Results of the Phase 2 Triac Trial II with Emcitate for MCT8 Deficiency	19/06	CI
Egetis awarded Promising Innovative Medicine designation in the UK for Emcitate® (tiratricol) for treatment of MCT8 deficiency	03/06	AQ
Egetis Receives Promising Innovative Medicine Designation in the UK for Emcitate® for Treatment of MCt8 Deficiency	03/06	CI
Bulletin from Egetis Therapeutics’ Annual General Meeting 2024	06/05	AQ
Egetis Therapeutics Q1 2024 - EU launch closing in	06/05	AQ
Egetis Therapeutics AB Reports Earnings Results for the First Quarter Ended March 31, 2024	03/05	CI
The Nomination Committee adjusts its proposal for the annual general meeting of Egetis Therapeutics AB (publ)	24/04	AQ
Egetis Therapeutics' : 2023 Annual Report published	15/04	PU
Egetis Therapeutics’ 2023 Annual Report published	15/04	AQ
Egetis Therapeutics : NOTICE OF ANNUAL GENERAL MEETING IN EGETIS THERAPEUTICS AB (PUBL)	29/03	PU
Egetis Therapeutics - Continued progress in Q4	23/02	AQ
Egetis Therapeutics AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	22/02	CI
Egetis Therapeutics AB Reports Earnings Results for the Full Year Ended December 31, 2023	22/02	CI
Egetis Therapeutics : – Corporate Presentation December 2023	27/12	PU
Egetis Therapeutics AB Appoints Laetitia Szaller as General Counsel and Head of Compliance	22/12	CI
Egetis recruits Laetitia Szaller as General Counsel and Head of Compliance	22/12	AQ
Transcript : Egetis Therapeutics AB - Analyst/Investor Day	19/12

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News PledPharma AB (publ) Nasdaq Stockholm

Equities

Summary

Filters